Focalpoint Ventures

The firm invests under the XEIA Venture Partners brand with a thesis it calls 'Human 3,' targeting the convergence of life sciences, AI, hardware, and deep tech to advance human health, wellbeing, and performance. Its portfolio companies combine these disciplines in ways that often defy traditional categorization.

XEIA Venture Partners focuses on early-stage startups. The firm has not publicly specified a preferred check size or series range, but its positioning points to seed and early-venture rounds for companies still forming their core scientific and product foundations.

The firm is explicitly concentrated on health, wellbeing, and performance — it does not invest in general SaaS, enterprise software, fintech, or consumer internet plays that fall outside the intersection of human biology and technology. Its narrow 'Human 3' mandate implicitly excludes sectors where the upgrade of the human body or mind is not the central value proposition.

The firm has not publicly named its investment committee or disclosed the identities of its general partners on its website or in available public filings. It signals an advisory network that includes a medicinal chemist, a psychoactive pharmacologist, and the director of MIT's Aging Brain Initiative, suggesting these domain experts inform technical evaluation.

Based on its thesis, deal flow likely depends on deep networks within academic and commercial life sciences, neurotechnology, and computational biology communities. The firm's association with advisors at institutions like MIT indicates a sourcing model rooted in scientific research hubs and frontier bio-hardware labs, though the firm has not described its sourcing process publicly.